SCHEMBL2820122

SCHEMBL2820122

CCOC(=O)c1cc2c(F)cc(F)cc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.50
ALDH1A1 P00352 5/20 0.50
HPGD P15428 4/20 0.50
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
HSD17B10 Q99714 1/20 0.50
NPC1 O15118 3/20 0.49
MAPT P10636 3/20 0.49
LMNA P02545 2/20 0.49
GAA P10253 2/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
GLA P06280 1/20 0.49
ATM Q13315 1/20 0.49
ALOX15 P16050 1/20 0.48
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
MMP13 P45452 5/20 0.46
MMP2 P08253 5/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29813118 0.88 KDM4E (0.54) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL23147929 0.88 KDM4E (0.54) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL22620763 0.86 KDM4E (0.48) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL31405949 0.86 KDM4E (0.48) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL4037610 0.86 KDM4E (0.48) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL22647645 0.85 KDM4E (0.47) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL30995200 0.85 ALDH1A1 (0.56) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL22620680 0.84 KDM4E (0.51) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL18299060 0.83 KDM4E (0.46) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL22647644 0.83 KDM4E (0.46) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106810488-B One class is used as GPR17 and CysLT1Compound of dual antagonist, preparation method and application thereof 中国科学院上海药物研究所 2021-02-19 CN disclosed
CN-101501053-B 1- (-D-glucopyranosyl) -3- (4-cyclopropylphenylmethyl) -4-haloindole derivatives and their use as SGLT inhibitors MITSUBISHI TANABE PHARMA CORP 2012-10-03 CN disclosed
US-7851617-B2 Indole derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-12-14 US disclosed
CN-101501053-A 1- (-D-glucopyranosyl) -3- (4-cyclopropylphenylmethyl) -4-haloindole derivatives and their use as SGLT inhibitors MITSUBISHI TANABE PHARMA CORP (JP) 2009-08-05 CN disclosed
US-20080255111-A1 Tissue Factor Production Inhibitor SANKYO COMPANY LIMITED (JP) 2008-10-16 US disclosed
US-20080027122-A1 Indole derivatives TANABE SEIYAKU CO., LTD. 2008-01-31 US disclosed
EP-1764075-A1 TISSUE FACTOR PRODUCTION INHIBITOR Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027122-A1 Indole derivatives SLC5A1, SLC5A2, SLC5A11 KDM4E 1709/4885ALDH1A1 398/4885HPGD 2385/4885
US-20080255111-A1 Tissue Factor Production Inhibitor PTAFR, PLAT, TFPI KDM4E 4805/4885ALDH1A1 4330/4885HPGD 1440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.